Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents

Takehiro Kawashiri1, Daisuke Kobayashi2, Nobuaki Egashira2, Takashi Tsuchiya3 & Takao Shimazoe1

Oxaliplatin frequently causes severe peripheral neuropathy as a dose-limiting toxicity. However, this toxicity lacks a strategy for prevention. Cystine/Theanine is a supplement, which includes precursors for the biosynthesis of glutathione. In this study, we investigated the effects of Cystine/Theanine on oxaliplatin-induced peripheral neuropathy using an in vivo model. Repeated injection of oxaliplatin (4 mg/kg intraperitoneally twice a week for 2 weeks) caused mechanical allodynia, cold hyperalgesia and axonal degeneration of the sciatic nerve in rats. Mechanical allodynia and axonal degeneration, but not cold hyperalgesia, were ameliorated by daily co-administration of Cystine (200 mg/kg orally (p.o.)) and Theanine (80 mg/kg p.o.). Moreover, co-administration of Cystine and Theanine to rats significantly increased the glutathione level in the sciatic nerve compared with the oxaliplatin group. Furthermore, Cystine and Theanine did not attenuate the tumour cytotoxicity of oxaliplatin in C-26 tumour cell-bearing mice. These findings suggest that Cystine and Theanine may be beneficial for preventing oxaliplatin-induced peripheral neuropathy.

Oxaliplatin, a platinum-based chemotherapeutic agent, is widely used for the standard treatment of colorectal, gastric, and pancreatic cancers, however frequently causes severe peripheral neuropathy. Acute neuropathy such as cold-related paraesthesia in hands, feet and the perioral region manifests within hours to days after oxaliplatin infusion. In almost cases, the cold-related acute neuropathy is transient and reversible1,2. Previous reports indicated that voltage-gated ion channels and transient receptor potential channels are involved in the acute neuropathy induced by oxaliplatin3–5. Sensory dysfunction as chronic neuropathy, which is a dose-limiting factor, occurs after repeated injections of oxaliplatin2,6. It is considered to be caused by morphological changes in neurons, such as axon degeneration and neuronal cell body damage7–9. However, no medications have been recommended to prevent chemotherapy-induced peripheral neuropathy10.

Cystine/Theanine, which is a supplement that contains l-Cystine (700 mg) and l-Theanine (280 mg), has been verified to affect adverse events, such as diarrhoea, oral mucositis and hand-foot syndrome in patients receiving cancer chemotherapy and during recovery after surgery11–14. Theanine is metabolised to glutamic acid and glutathione, which has an antioxidative effect, is synthesised from cysteine and glutamic acid. Many studies have indicated that oxidative stress plays a role in oxaliplatin-related peripheral neuropathy15–17. Furthermore, glutathione has reduced oxaliplatin-induced peripheral neurotoxicity in clinical studies18,19. Therefore, we investigated the neuroprotective efficacy of Cystine/Theanine on oxaliplatin-induced peripheral neuropathy in rodent models.

Results
Effect of Cystine/Theanine on mechanical allodynia induced by oxaliplatin in rats. On the von Frey test, repeated administration of oxaliplatin (4 mg/kg i.p.) significantly reduced the paw withdrawal threshold compared with those with the vehicle treatment on days 25 and 29 (P<0.01; Fig. 1A). Co-treatment with...
Cystine (200 mg/kg p.o.) and Theanine (80 mg/kg p.o.) significantly improved the reduction in the thresholds caused by oxaliplatin on both days ($P < 0.01$; Fig. 1A).

**Effect of Cystine/Theanine on cold hyperalgesia induced by oxaliplatin in rats.** On the acetone test, the administration of oxaliplatin significantly increased the number of withdrawal responses to cold stimulus compared with those in the vehicle group on days 4 and 29 ($P < 0.01$; Fig. 1B). Co-treatment with Cystine and Theanine did not improve the increase in the number of withdrawal responses caused by oxaliplatin on both days.

**Effect of Cystine/Theanine on axonal degeneration of sciatic nerves induced by oxaliplatin in rats.** The axon circularities in the toluidine blue-stained sections of rat sciatic nerves significantly decreased in oxaliplatin group compared to the vehicle group on day 30 ($P < 0.01$; Fig. 2B). Co-administration of Cystine and Theanine significantly alleviated oxaliplatin-induced axon circularity reduction ($P < 0.01$; Fig. 2B). Neither the diameter of nerve fibres nor the density of fibres was changed by the administration of oxaliplatin (Fig. 2C and D). Although oxaliplatin induced an increase in the $g$-ratio, the ratio of the fibre diameter to the axonal diameter, and a decrease in the myelin sheath thickness ($P < 0.01$), co-administration of Cystine and Theanine did not change the $g$-ratio or the myelin thickness compared to the oxaliplatin group (Fig. 2E and F).

**Effect of Cystine/Theanine on the glutathione level in rat sciatic nerves.** Repeated administration of oxaliplatin decreased the total glutathione content in the sciatic nerve on day 30 ($P < 0.05$; Fig. 3). Co-administration of Cystine and Theanine significantly reversed the reduction in the glutathione level compared with the oxaliplatin group ($P < 0.05$; Fig. 3).
Effect of Cystine/Theanine on the antitumor activity of oxaliplatin in tumor cell-bearing mice. Repeated administration of oxaliplatin treatment (6 mg/kg i.p.) significantly attenuated tumor growth compared to the vehicle ($P<0.01$; Fig. 4). Co-treatment with Cystine and Theanine (420 mg/kg/day; Cystine 300 mg/kg/day, Theanine 120 mg/kg/day; p.o.) had no effect in the inhibitory effect of oxaliplatin (Fig. 4).
Discussion

Cystine/Theanine attenuated oxaliplatin-induced mechanical allodynia in rats, which mimics chronic neuropathy in a clinical setting. However, these amino acids did not reverse cold hyperalgesia, which was used to simulate oxaliplatin-related acute neuropathy, in this study. A previous study indicated there is a distinct difference between metabolites responsible for acute and chronic neuropathy caused by oxaliplatin; oxalate and platinum metabolites are involved in cold hyperalgesia and mechanical allodynia, respectively. Other studies have reported that voltage-gated ion channels and transient receptor potential channels are involved in oxaliplatin-induced acute neurotoxicity. However, it is thought that chronic neuropathy is caused by morphological changes in neurons, such as axon degeneration, neuronal cell body damage and demyelinating disease. Our morphological experiment showed that Cystine/Theanine reversed the decrease in the circularity of nerve fibres but not the abnormalities in the g-ratio and myelin sheath thickness. It has been confirmed that the morphological changes are parallel to the behavioural changes in previous studies using oxaliplatin-induced peripheral neuropathy model. The averages of circularities were 0.758 and 0.736 in vehicle and oxaliplatin groups, respectively. The difference, 0.022, was seemingly a mild change. However, it was a decent difference in comparison with the changes of the circularities in previous reports used diabetic neuropathy models, whose differences between control and diabetic rats were 0.023–0.048, and oxaliplatin-induced neuropathy models, whose differences between control and neuropathy rats were 0.015–0.041. Hence, it is thought that Cystine/Theanine ameliorates chronic neuropathic symptoms via protective effects against axon disorders (axonopathy) but not myelin abnormalities (myelinopathy).
Many previous basic studies support that oxidative stress plays a role in oxaliplatin-related peripheral neuropathy. We have also shown the neuroprotective effects of some drugs, which had antioxidative activities, on oxaliplatin-induced peripheral neuropathy in rats and cultured cell lines. Moreover, glutathione, which has an antioxidative effect, has reduced oxaliplatin-induced peripheral neurotoxicity in clinical studies. Furthermore, oral administration of Cystine/Theanine increased the glutathione level in sciatic nerves in this study. Kurihara and colleagues indicated that treatment of Cystine/Theanine increases the glutathione level in mouse liver. Cystine and theanine are metabolized in the body to cysteine and glutamate, respectively. It is thought that glutathione is synthesized from cysteine and glutamate in monocytes, macrophages and dendritic cells. Collectively, the increase in biosynthesis of glutathione from Cystine and Theanine might play an important role in the neuroprotective effect against oxaliplatin-induced neurotoxicity. Some reports have also indicated the possibility that glutathione conjugates to metabolites of oxaliplatin and inactivates platinum metabolites in cells. Therefore, not only antioxidative activity but also conjugation to platinum might be involved in the amelioration of oxaliplatin-related neurotoxicity. Furthermore, some studies have reported that cysteine and theanine reverse the increases in inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor α (TNF-α), in the mouse surgical model and the gut ischemia–reperfusion model. The increases in IL-6 and TNF-α have reported in also cell and animal models of oxaliplatin-induced neurotoxicity. It is also possible that the down-regulation of such inflammatory cytokines is partly involved in the neuroprotective effects of Cystine and Theanine.

Our study focused on the effects of oxaliplatin and Cystine/Theanine on the peripheral nerve system. However, it has been reported that oxaliplatin enhances the oxidative stress in also the central nervous system, such as brain and spinal cord. Cystine can cross the blood–brain barrier (BBB) via L-type amino acid transporter 1 (LAT1) and LAT2. Cystine is taken up by BBB endothelial cells via the complex of the cystine/glutamic acid transporter (xCT) and the heavy chain of 4F2 cell surface antigen (4F2hc) subunits. It is thought that cysteine which decomposed from cysteine in endothelial cells is transported into the brain via LAT1. Taken together, it may be possible that systemic administration of Cystine/Theanine increases GSH in also the spinal cord and brain, and as a result, the neuropathy is suppressed via antioxidant action in the central nervous system.

The influence of Cystine/Theanine on anticancer activity of oxaliplatin was assessed in this study, and no impairment was observed in the tumour cell-bearing mice. Hence, Cystine/Theanine is unlikely to weaken the antineoplastic efficacy of oxaliplatin.

“Coasting” which means that the peripheral neuropathy continues to worsen for a time period despite cessation of therapy has been reported in patients treated with oxaliplatin. In also our animal model, the mechanical allodynia persists approximately 20 days after the final administration of oxaliplatin. However, the behavioural tests were assessed only until day 29 in this study. It is important to perform additional studies whether the neuroprotective effects of Cystine/Theanine is sustainable in the longer term. Moreover, further studies such as biochemistry and conduction velocity are also needed.

The present study demonstrates that repeated administration of Cystine/Theanine ameliorated oxaliplatin-induced mechanical allodynia and axon disorders without inhibiting antitumor efficacy in rodents. Therefore, Cystine/Theanine may be a preventive option for oxaliplatin-induced peripheral neuropathy.

Methods

Animals. Six-week-old male Sprague–Dawley rats weighing 200–250 g were used for the oxaliplatin-induced peripheral neuropathy model. Six-week-old male BALB/c mice weighing 15–25 g were used for the in vivo tumour growth model. Animals were housed in groups of 4–5 per cage with lights on from 7:00 to 19:00. Animals had free access to food and water in their home cages.

Drugs. Oxaliplatin (Elplat) was obtained from Yakult Honsha Co., Ltd. (Tokyo, Japan). Cystine/Theanine was generously obtained from Ajinomoto Co., Inc. (Tokyo, Japan). In the oxaliplatin-induced peripheral neuropathy model, oxaliplatin (4 mg/kg) or a vehicle (5% glucose solution) was injected intraperitoneally (i.p.) twice a week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22 and 23). Cystine/Theanine (Cystine 200 mg/kg and Theanine 80 mg/kg) or a vehicle (5% methyl cellulose) was administered orally (p.o.) every day for 4 weeks (days -2 to 28). Each drug was administered at a volume of 1 mL/kg. The doses of these drugs were determined based on previous reports. Ten rats per group were employed for the von Frey test and the acetone test.

Von Frey test for mechanical allodynia. The von Frey test was used to evaluate the effect of Cystine/Theanine on mechanical allodynia. The test was performed before the first drug administration (day -2) and on days 4, 11, 18, 25 and 29 before drug administration. Each rat was placed in a wire mesh box for 30 min for adaptation before the test. Von Frey filaments (Aesthesio; DanMic Global LLC., San Jose, CA, USA) were applied to the mid-plantar skin of each hind paw for 6 s, and the paw withdrawal thresholds were determined using a modified up-down method as previously described.

Acetone test for cold hyperalgesia. The acetone test was performed to assess cold hyperalgesia. The test was performed only twice on days 4 and 29 because too many tests were distressing to the animals. The method was described in a previous report. Rats were adapted to the wire mesh box in the same manner as that in the von Frey test. Acetone (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was sprayed onto the plantar skin, and the number of withdrawal responses was counted for 40 s.
Assessment of sciatic nerve axonal degeneration. Sciatic nerves were harvested from three rats per group that were anaesthetised with sevoflurane (FUJIFILM Wako Pure Chemical Corporation) on day 30. After fixation of the samples in 2% (w/v) glutaraldehyde followed by 8% (w/v) sucrose substitution, nerves were embedded in Epon. Samples were sliced and stained with toluidine blue. Sample sections were evaluated with light microscopy (BX51, Olympus, Tokyo) and analysed using ImageJ software version 1.51 (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA). The circularity, density of the nerve fibres, and the g-ratio were calculated by the Eqs. (1), (2) and (3), respectively.

\[
\text{Circularity} = \frac{4 \times \pi \times \text{(axonal area)}}{\text{(Axonal perimeter)}^2}
\]  
\[
\text{(Density of nerve fibres)} = \frac{\text{(Number of axonal fibres)}}{\text{(Sciatic nerve area)}}
\]  
\[
(g - \text{Ratio}) = \frac{[(\text{Maximum of fibre diameter}) + (\text{minimum of fibre diameter})]/2}{[(\text{Maximum of axonal diameter}) + (\text{minimum of axonal diameter})]/2}
\]

Measurement of the glutathione level in sciatic nerves. Sciatic nerves were harvested from rats on day 30. The tissues were sonicated in 1 mL of saline and centrifuged at 15,000 rpm for 10 min. The total glutathione content in the supernatants was measured with a GSSG/GSH Quantification Kit (Dojindo Laboratories, Kumamoto, Japan).

Assessment of the tumour growth in tumour-bearing mice. Murine colon adenocarcinoma (C-26) cells were obtained from the Cell Resource Centre for Biomedical Research, Tohoku University (Miyagi, Japan). C-26 cells were grown in Roswell Park Memorial Institute 1640 medium containing 2 mM l-glutamine and 10% foetal bovine serum. The cells were cultured in humidified air supplemented with 5% CO2 at 37 °C. C-26 cells (1.5 × 10⁶ cells) were subcutaneously implanted in the right paws of BALB/c mice. Three days after the implantation of the tumour cells, drug administration began. Oxaliplatin (6 mg/kg i.p.) was administered on days 1, 2, 8 and 9 and Cystine/Theanine (420 mg/kg/day; 210 mg/kg twice daily p.o.) was administered every day on days 3, 5, 7, 9, and 11. The dose of oxaliplatin was determined based on previous reports. Ten tumour-bearing mice per group were employed. The tumour volumes were measured on days 1, 3, 5, 8, 10 and 12 and were calculated as follows: volume (mm³) = π/6 × thickness (mm) × length (mm) × width (mm).

Statistical analysis. The results are expressed as the mean ± standard error of the mean. Statistical analyses were performed using a one-way analysis of variance followed by the Tukey–Kramer test (Statview; Abacus Concepts, Berkeley, CA, USA) to determine the differences between the groups. A probability level of P < 0.05 was accepted as statistically significant.

Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 30 April 2020; Accepted: 17 July 2020
Published online: 29 July 2020

References
1. Wilson, R. H. et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 20, 1767–1774 (2002).
2. Argyriou, A. A., Bruna, J., Marmiroli, P. & Cavalletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 82, 51–77 (2012).
3. Stitt, R. et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current. Proc. Natl. Acad. Sci. U. S. A. 109, 6704–6709 (2012).
4. Kagia, A., Tsingotjidou, A., Emmanouilides, C. & Theophilidis, G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 29, 1100–1106 (2008).
5. Kawashiri, T. et al. Type Ca2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol. Pain 8, 7 (2012).
6. Pasetto, L. M., D’Andrea, M. R., Rossi, E. & Monfardini, S. Oxaliplatin-related neuropathy: How and why? Crit. Rev. Oncol. Hematol. 59, 159–168 (2006).
7. Lehky, T. J., Leonard, G. D., Wilson, R. H., Grem, J. L. & Floeter, M. K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29, 387–392 (2004).
8. Jamieson, S. M., Liu, J., Connor, B. & McKeage, M. J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother. Pharmacol. 56, 391–399 (2005).
9. Tatsusumi, K. et al. Oxaliplatin induces hypomyelination and reduced neuregulin 1 expression in the rat sciatic nerve. Neurosci. Res. 80, 86–90 (2014).
10. Hershman, D. L. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 32, 1941–1967 (2014).
11. Miyachi, T. et al. Perioperative oral administration of Cystine and Theanine enhances recovery after distal gastrectomy: a prospective randomized trial. J. Parenter. Enter. Nutr. 37, 384–391 (2013).
12. Tsuchiya, T. et al. Oral administration of the amino acids Cystine and Theanine attenuates the adverse effects of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. Int. J. Clin. Oncol. 21, 1085–1090 (2016).

13. Hamaguchi, R. et al. Efficacy of oral administration of Cystine and Theanine in patients with colorectal cancer undergoing capcetabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial. BMJ Open 8, e021442 (2018).

14. Hamaguchi, R. et al. Efficacy of oral administration of Cystine and Theanine in colorectal cancer patients undergoing capcetabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03). Support Care Cancer 28, 3649–3657 (2020).

15. McQuade, R. M. et al. Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173, 3502–3521 (2016).

16. Di Cesare Mannelli, L. et al. Effect of the SOD mimetic MnSOD in in vitro and in vivo oxaliplatin toxicity: possible aid in chemotheraphy induced neurotoxicity. Free Radiol. Biol. Med. 93, 67–76 (2016).

17. Di Cesare Mannelli, L., Zanardelli, M., Failli, P. & Ghelardini, C. Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neurotoropy? Free Radiol. Biol. Med. 61, 143–150 (2013).

18. Cascini, S. et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 20, 3478–3483 (2002).

19. Kita, P. et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 20, 396–402 (2009).

20. Sakurai, M. et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical alldynia. Pain 147, 165–174 (2009).

21. Yamamoto, S. et al. Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Sci. Rep. 7, 9661 (2017).

22. Usii, S. et al. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur. J. Cancer 48, 1407–1413 (2012).

23. Fujita, S. et al. Exenatide facilitates recovery from oxaliplatin-induced peripheral neuropathy in rats. PLoS ONE 10, e0141921 (2015).

24. Kawashiri, T., Shimizu, S., Shigematsu, N., Kobayashi, D. & Shimazoe, T. Donepezil ameliorates oxaliplatin-induced neuropathy via a neuroprotective effect. J. Pharmacol. Sci. 140, 291–294 (2019).

25. Miyagi, A. et al. Dimethyl fumarate attenuates oxaliplatin-induced peripheral neuropathy without affecting the anti-tumor activity of oxaliplatin in rodents. Biol. Pharm. Bull. 42, 638–644 (2019).

26. Shigematsu, N. et al. Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro. Sci. Rep. 10, 6734 (2020).

27. Kato, N., Mizuno, K., Makino, M., Suzuki, T. & Yagihashi, S. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res. Clin. Pract. 81, 109–110 (2010).

28. Shibata, T. et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 57, 3099–3107 (2008).

29. Kawashiri, T. et al. Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro. J. Pharmacol. Sci. 137, 202–211 (2018).

30. Kurihara, S., Shibahara, S., Arisaka, H. & Akiyama, Y. Enhancement of antigen-specific immunoglobulin G production in mice by co-administration of L-cystine and L-theanine. J. Vet. Med. Sci. 69, 1263–1270 (2007).

31. Kurihara, S., Shibahara, S., Tanaka, K. A. Cystine and theanine: amino acids as oral immunomodulatory nutrients. Springerplus 2, 635 (2013).

32. Kweekel, D. M., Gelderblom, H. & Guchelaar, H. J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Res. 31, 90–105 (2005).

33. Graham, M. A. et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6, 1205–1218 (2000).

34. Shibakusa, T. et al. Enhancement of postoperative recovery by preoperative oral co-administration of the amino acids, Cystine and Theanine, in a mouse surgical model. Clin. Nutr. 31, 555–561 (2012).

35. Miyakuni, T. et al. Cystine and Theanine improve survival after gut ischemia-reperfusion. Ann. Nutr. Metab. 73, 131–137 (2018).

36. Massicot, F. et al. P2X7 cell death receptor activation and mitochondrial impairment in oxaliplatin-induced apoptosis and neuronal injury: cellular mechanisms and in vivo approach. PLoS ONE 8, e66830 (2013).

37. Duan, Z., Su, Z., Wang, H. & Pang, X. Involvement of pro-inflammatory signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain. Mol. Pain 14, 1744806918769426 (2018).

38. Zanardelli, M. et al. Oxaliplatin neurotoxicity involves peroxisome alterations. PPARy agonism as preventive pharmacological approach. PLoS ONE 9, e102758 (2014).

39. Kim, S. T. et al. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. Life Sci. 130, 81–87 (2015).

40. Waseem, M., Tabassum, H. & Parvez, S. Neuroprotective effects of melatonin as evidenced by abrogation of oxaliplatin induced behavioral alterations, mitochondrial dysfunction and neurotoxicity in rat brain. Mitochondrion 30, 168–176 (2016).

41. Areti, A., Komiritschty, P., Akuotha, M., Malik, R. A. & Kumar, A. Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. J. Pineal Res. 62, e12393 (2017).

42. Miao, F. et al. Engagement of microRNA-155 in exaggerated oxidative stress signal and TRPA1 in the dorsal horn of the spinal cord and neuropathic pain during chemotherapeutic oxaliplatin. Neurotox. Res. 36, 712–723 (2019).

43. Celik, H. et al. Lycopene protects against central and peripheral neuropathy by inhibiting Oxaliplatin-induced ATF-6 pathway, apoptosis, inflammation and oxidative stress in brains and sciatic tissues of rats. Neurotox. Res. 80, 29–40 (2020).

44. Yokogoshi, H., Kobayashi, M., Mochizuki, M. & Terashima, T. Effect of theanine, γ-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem. Res. 23, 667–673 (1998).

45. Yamamoto, S. et al. The involvement of L-type amino acid transporters in theanine transport. Biosci. Biotechnol. Biochem. 76, 2320–2325 (2012).

46. Sato, H., Tamba, M., Ishii, T. & Bannai, S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274, 11455–11458 (1999).

47. Shih, A. Y. et al. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative damage and cell proliferation. J. Neurosci. 26, 10514–10523 (2006).

48. Wade, L. A. & Brady, H. M. Cysteine and cystine transport at the blood-brain barrier. J. Neurochem. 37, 730–734 (1981).

49. Killian, D. M. & Chikhale, P. J. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. Neurosci. Lett. 306, 1–4 (2001).

50. Choi, J., Kong, K., Mozaffar, T. & Holcombe, R. F. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 17, 103–105 (2006).

51. Kawashiri, T. et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur. J. Pain 15, 344–350 (2011).

52. Zimmermann, M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109–110 (1983).
Acknowledgements
This work was partly supported by JSPS KAKENHI (20K07198).

Author contributions
T.K. designed and performed the experiments, analysed the data, and wrote the study. D.K., N.E., T.T., and T.S. provided critical advice on the experiments and data interpretation.

Competing interests
This study was supported by grants from Ajinomoto Co. Inc.

Additional information
Correspondence and requests for materials should be addressed to T.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020